An impressive crowd gathered yesterday (November 21) at Chiesi Pharmaceutical Group for the much-anticipated launch of its Biotech Center of Excellence, bringing the future of medicine to Parma.
Guests, including the Vice Minister of Trade and Made in Italy, Valentino Valentini, attended the celebration of the start of work on the building of the new Italian and International Center of Excellence for the manufacture of biological medicines.
Expected to open and be fully operational in 2024, the center will specialize in the development and production of active ingredients for monoclonal antibodies (from a type of immune cell produced through recombinant DNA techniques), enzymes and other proteins.
Chiesi focuses on biological medicine
“The success of Made in Italy is made possible by the fact that Chiesi is the first among private companies to invest in research and development in Italy: 20% of turnover, almost half a billion euros in 2022 and number of patents in first place.
“The Chiesi Group is now focusing on biological medicines, including monoclonal antibodies, with an 85 million euro investment in an international center of excellence in Parma, ensuring a corporate culture focused on patients, innovation and maximum environmental sustainability”, says Valentini.
Chiesi is keen to further develop the expertise already existing in Italy and attract new talent and technical expertise to work from cells to pharmaceuticals and packaging for the global market.
Chiesi is interested in developing skills
The creation of the Biotech Center of Excellence, Chisi believes, is a necessary response to the challenges highlighted by the pandemic, which reveals the need to improve the resilience of healthcare systems, including improving sustainability.
Today, only 22% of all new treatments developed worldwide originate in European countries, and this is partly due to slow research and development and investment across the region.
Alberto Chiesi, president of the family-run Chiesi Group, said: “Today we are proud to present this new Center of Excellence in the presence of local, regional and national institutions. For Chiesi, it is always essential to invest in research with the aim of leading our country and Europe in access to manufacturing and innovation. Moreover, the new biotech center represents a strong message of growth for Italy and especially for the community of Parma, where Chisi was founded and where its headquarters are still located.”
Emilia-Romagna will compete at international level
The event, held at the Chiesi San Leonardo production site in Parma, where the new center is being built, was attended by Valentino Valentini, Emilia-Romagna Region President Stefano Bonacchini, Councilor Vincenzo Cola, Parma Mayor Michele Guerra, Farm Industry President Marcelo Cattani and the Group’s top management .
“Research, innovation, and new technologies are the strategic drivers that will enable an area like Emilia-Romagna to compete internationally now and in the near future. For this reason, the opening of this center is great news that will enrich our region with another place of excellence in medicine. As an organization, we want to stand by the entrepreneurial reality that invests in good jobs, innovation and research, giving them more opportunities.
“Starting with a regional system that has prospered, with the opening on Thursday at the Technopole of Bologna of the European supercomputer Leonardo, the fourth largest in the world in terms of computing power, an extraordinary infrastructure, at the service of Italy and Europe, including pharmaceuticals and biotechnology as many sectors with the greatest potential including,” said Stefano Bonacchini, president of the Emilia-Romagna region
Chiesi’s commitment to research in Italy
The agency says that for Italy and Europe to be leaders in access to raw materials and innovation, it is fundamental that European and national institutions work to create rules and regulations that are future-proof. Furthermore, it said, it is also important to initiate work to maintain strong incentive systems that encourage scientific progress, technology and innovative pharmaceuticals. In order to focus on the value brought to patients and healthcare systems, efforts need to be made for a regulatory ecosystem that looks past the notion of assessing innovation based on technology.
Antonio Magnelli, head of the Chiesi Group’s global manufacturing division, said: “With the Biotech Center the company wants to internalize its expertise for an effective research facility that can develop new drugs and facilitate integration with our manufacturing plants. region. Our aim is not to compete with big multinationals, but to become a center of excellence in our molecules. The biotech center will not only develop in the field of biotechnology; It will be developed with the same privileges as other facilities of the company. By investing in biotech, we are investing in the medicine of the future, preparing for the healthcare needs of the future.”
The meeting was an opportunity to celebrate Chiesi’s commitment to research in Italy; In fact, the group continues to invest in the region, carrying out projects that create valuable and new highly qualified jobs. The new therapeutic opportunities offered by the biotech center of excellence will allow the company to become a major player in the biopharmaceutical sector, an industry that has been growing steadily for nearly 10 years.